Second Quarter 2017 Financial Results and Business Update · representaons and warranFes as may arise under law upon distribuFon of any prospectus or similar oﬀering document by

August9,2017

SecondQuarter2017FinancialResultsandBusinessUpdate

©2017IntrexonCorp.Allrightsreserved.2

SafeHarborStatementSomeofthestatementsmadeinthispresentaFonareforward-lookingstatementsthatinvolveanumberofrisksanduncertainFesandaremadepursuanttotheSafeharborProvisionsofthePrivateSecuriFesLiFgaFonReformActof1995.Theseforward-lookingstatementsarebaseduponIntrexon’scurrentexpectaFonsandprojecFonsaboutfutureeventsandgenerallyrelatetoIntrexon’splans,objecFvesandexpectaFonsforthedevelopmentofIntrexon’sbusiness. AlthoughmanagementbelievesthattheplansandobjecFvesreflectedinorsuggestedbytheseforward-lookingstatementsarereasonable,allforward-lookingstatementsinvolverisksanduncertainFesandactualfutureresultsmaybemateriallydifferentfromtheplans,objecFvesandexpectaFonsexpressedinthispresentaFon.TheserisksanduncertainFesinclude,butarenotlimitedto,(i)Intrexon’scurrentandfutureECCsandjointventures;(ii)Intrexon’sabilitytosuccessfullyenternewmarketsordevelopaddiFonalproducts,whetherwithitscollaboratorsorindependently;(iii)actualoranFcipatedvariaFonsinIntrexon’soperaFngresults;(iv)actualoranFcipatedfluctuaFonsinIntrexon’scompeFtors’oritscollaborators’operaFngresultsorchangesintheirrespecFvegrowthrates;(v)Intrexon’scashposiFon;(vi)marketcondiFonsinIntrexon’sindustry;(vii)thevolaFlityofIntrexon’sstockprice;(viii)Intrexon’sability,andtheabilityofitscollaborators,toprotect Intrexon’s intellectual property and other proprietary rights and technologies; (ix) Intrexon’s ability, and the ability of its collaborators, to adapt tochanges in lawsor regulaFonsandpolicies; (x) theoutcomesofpendingand future liFgaFon; (xi) therateanddegreeofmarketacceptanceofanyproductsdevelopedbya collaboratorunderanECCor througha jointventure; (xii) Intrexon’sability to retainand recruit keypersonnel; (xiii) Intrexon’sexpectaFonsrelated to the use of proceeds from its public offerings and other financing efforts; (xiv) Intrexon’s esFmates regarding expenses, future revenue, capitalrequirementsandneedsforaddiFonalfinancing;and(xv)Intrexon’sexpectaFonsrelaFngtoitssubsidiariesandotheraffiliates.Foradiscussionofotherrisksand uncertainFes, and other important factors, any of which could cause Intrexon’s actual results to differ from those contained in the forward-lookingstatements,seethesecFonenFtled”RiskFactors“inIntrexon’sAnnualReportonForm10-K,aswellasdiscussionsofpotenFalrisks,uncertainFes,andotherimportant factors in Intrexon’s subsequent filingswith the SecuriFes and ExchangeCommission.All informaFon in this presentaFon is as of thedateof therelease,andIntrexonundertakesnodutytoupdatethisinformaFonunlessrequiredbylaw.Non-GAAPFinancialMeasuresThispresentaFonpresentsAdjustedEBITDA,whicharenon-GAAPfinancialmeasureswithinthemeaningofapplicablerulesandregulaFonsoftheSecuriFesandExchange Commission (SEC). For a reconciliaFon of Adjusted EBITDA to net loss a`ributable to Intrexon in accordance with generally accepted accounFngprinciplesandforadiscussionofthereasonswhythecompanybelievesthatthesenon-GAAPfinancialmeasuresprovideinformaFonthatisusefultoinvestorsseethetablesbelowunder“ReconciliaFonofGAAPtoNon-GAAPMeasures.” SuchinformaFonisprovidedasaddiFonalinformaFon,notasanalternaFvetoIntrexon’sconsolidatedfinancialstatementspresentedinaccordancewithGAAP,andisintendedtoenhanceanoverallunderstandingoftheCompany’scurrentfinancialperformance.

©2017IntrexonCorp.Allrightsreserved.IntrexonCorporaFonissharingthefollowingmaterialsforinformaFonalpurposesonly.SuchmaterialsdonotconsFtuteanoffertosellorthesolicitaFonofanoffertobuyanysecuriFesofIntrexon.AnyofferandsaleofIntrexon’ssecuriFeswillbemade,ifatall,onlyupontheregistraFonandqualificaFonofsuchsecuriFesunderallapplicablefederalandstatesecuriFeslawsorpursuanttoanexempFonfromsuchrequirements.TheaàchedinformaFonhasbeenpreparedingoodfaithbyIntrexon.However,IntrexonmakesnorepresentaFonsorwarranFesastothecompletenessoraccuracyofanysuchinformaFon.AnyrepresentaFonsorwarranFesastoIntrexonshallbelimitedexclusivelytoanyagreementsthatmaybeenteredintobyIntrexonandtosuchrepresentaFonsandwarranFesasmayariseunderlawupondistribuFonofanyprospectusorsimilarofferingdocumentbyIntrexon.

Forward-LookingStatements

Collabora;ons,MarketableProducts&SectorsUpdateAndrewLast,Ph.D.–ChiefOperaFngOfficer


Precigen:Biotech2.0PlagormforHumanHealth

•  Intrexonhasassembledtheworld’sleadingtechnologyplaJormforprogrammingandengineeringthemostpervasivecodeontheplanet

•  Precigenwillu;lizeplaJormtobuildnextgenera;ontherapeu;cproductsfasterandcosteffec;vely

•  Broadpipelineofclinicalandpre-clinicalprograms,bothpartneredandun-partnered


NewCollaboraFons:MicrobialExpressionPlagorms

June2017-Enteredintoanexclusivecollabora;onwithJohnsonMaUhey(LSE:JMAT),agloballeaderinsciencethatenablescleanerair,improvedhealthandmoreefficientuseofnaturalresources,focusedonthedevelopmentofmicrobialstrainsforfermentaFveproducFonofpepFde-basedacFvepharmaceuFcalingredientsMay2017-Enteredintoaresearchcollabora;onagreementwithHuvepharmaEOOD,aglobalpharmaceuFcalcompanywithafocusondeveloping,manufacturing,andmarkeFnghumanandanimalhealthproducts,fortheuFlizaFonandfirstcommercialapplicaFonofIntrexon’sproprietaryfungalexpressionplagormtoproduceanewanimalfeedenzymedevelopedbyHuvepharma


EnviroFlight:BSFLarvaeProducFonFacilityinUS

•  EnviroFlight-aJointVenturebetweenIntrexon&DarlingIngredients(NYSE:DAR)o  ConstrucFonoflargestcommercial-scale

blacksoldierfly(BSF)larvaeproducFonfacilityinUSbeganinMay2017

o  SignificantlyexpandproducFonofadvancedingredientsforsustainablefeedandnutriFonderivedfromBSFlarvae

o  Supportsdevelopmentofsustainablehigh-nutriFonBSFingredientsforthe$60Bglobalanimalfeedindustry

•  Ini;alcapacityfromUSplantexpectedinQ1’2018o  ProducFonwillbetargetedtowardlivestock,

petfoodandaquaculturemarkets


AquAdvantage®Salmon

AquAdvantage®SalmonFirstengineeredfoodanimalapprovedby

USFDA/HealthCanada

•  AquaBountyenteredintoanagreementtopurchasecertainassetsofBellFishCompanyo  Land-basedfarmingfacilityinAlbany,Indiana

o  Expectedannualcapacityof1200metrictonsà>$10millionayearinpotenFalsaleswithpotenFalforexpansion

o  AquaBountyevaluaFngaddiFonalopportuniFesforlargerproducFonfaciliFesinUSandCanada

•  AdvantagesofAquAdvantage®plaJormo  LowerproducFoncostdrivenbyfastergrowthrateandless

feedrequirement

o  NovaccinesoranFbioFcs

o  Land-basedproducFonenables“produc(onanywhere”

o  PotenFalforlowersupplyfluctuaFonsandsteadyprices

•  Atlan;csalmonmarketinU.S.es;matedat>$2billiono  AlmostallcommerciallyavailableAtlanFcsalmonisfarmedo  USaloneimportsover200,000tonsoffarmedAtlanFc

salmonannually


CommercialLaunchinFall2017

CommerciallaunchoffreshslicedArc;c®applesinUSinFallof2017

Non-chemical,preserva(ve-freeapproachtonon-browning

Nochangetoappletaste/textureFreshslicedapplemarketinUSes(matedat~$500millioninsales


ArcFc®Non-browningPlagorm

Arc;c®AppleFirstUSDAapprovednon-browningapplewithout

useofchemicaloranFoxidanttreatments

•  Plan;ngprogressandoutlook:o  AnFcipateplanFngover250,000ArcFc®apple

treesduring2017andover500,000in2018

o  Planningfor4millionArcFc®appletreestobeplantedbyyearend2020

•  Commitmenttodevelopment:o  Completed2017staffingandlabfacilitybuild-out

planstosupportFssuecultureandmolecularbiologyacFviFes

•  Expandingapplica;onsofnon-browningplaJorm:o  ProducFoncostadvantagegivennoneedfor

preservaFvecoaFngso  AddiFonalfruits(cherries,pearsandavocados)o  Vegetables(leGuce)


BroadApplicaFonofInnovaFveArcFc®SoluFon

•  UniqueArc;cAdvantage™solu;oncreatesbenefitsforcommercialtreefruitvarie;esacrosstheen;resupplychain,fromgrowerstoconsumers

•  Conveniencedrivesconsumerpurchaseselec;on,especiallyinhealthysnackmarket

•  Posi;velyimpactfoodwaste,lesseningthecurrent40%ofappleswasted


Friendly™Aedes

Friendly™AedesScalableenviro-friendlymosquitosoluFontosuppressthedisease-carryingAedesaegyp(

•  Receivedposi;veevalua;onforEuropeanStandardinrela;ontohumanhealthandtheenvironmento  TheNaFonalInsFtuteofPublicHealthandthe

Environment,Netherlands(RIVM)publishedreportconcludingOxitec'sFriendly™mosquitoeswouldposenegligibleriskstohumanhealthandtheenvironment

o  France’sHighCouncilforBiotechnologypublishedsupporFveposiFon

•  Ongoinggeographicexpansionin2017o  Brazil–SignedmulF-yearcontractinJuizdeFora,the

secondBrazilianmunicipality&firstcityinMinasGeraiso  Colombia-AnnouncedMOUinComuna16region,anarea

of>104,000residentsinMunicipalityofSanFagodeCalio  India–IniFatedoutdoorcagedtrialstodemonstratethe

efficacyofFriendly™mosquitoesincollaboraFonwithGangabishanBhikulalInvestmentandTradingLimited

o  ExpecttoiniFatenewdeploymentsinexisFng&newregions


DurableSuppressionwithOxitec’sSoluFon

Over80%suppressionofAedesaegyp(inCECAP/EldoradoPiracicaba,Brazilmaintainedinsecondyearwithreleaseofnearly60%lessOxitecmosquitoesascomparedtoyearone

Levelofcontrolillustra(veofstrengthanddurabilityofOxitec’ssolu(on

Favorablepublicopinionwith93%ofci(zenssuppor(ngOxitec’ssolu(ons*

*CW7MarketResearchInsFtutesurvey

Aedesaegyp*wildlarvae(Larvae/trap;4weekaverage)


IntrexonMethaneBioconversionPlagorm

Intrexonhasdevelopeddisrup;veMBPtechnologythatenablestheprofitableuseoflowcostnaturalgastoreplaceoil

asthefeedstockforseveralhighvalueindustrialproducts.

NeedforcleanerburningfuelsinautomoFveandotherindustries

Gas-to-liquidsconversioncurrentlyreliesoncostly,energy-intensiveprocesses

OilsuppliesdesFnedfordepleFon

NegaFveeco-impactfromgasflaring

HighCapex&HighOpex


SignificantGas-to-LiquidsOpportunitythroughMBP

Intrexon’sEngineeredMethanotrophsChemicalsachieved:•  2,3Butanediol*•  Isobutyraldehyde*•  1,4Butanediol*•  Isoprene

NaturalGasFeedstock

Fuelsachieved:•  Isobutanol*•  Farnesene

MBPplagormhasachievedsixdifferentmoleculestodate.ThefourmoleculesacFvelyunderdevelopment(*)withIntrexon’sMBPtechnology

haveacumulaFveTotalAddressableMarketofover$100billion.


2,3Butanediol(BDO)ProgressUpdate

2,3butanediol

Methane bioconversion

Catalytic conversion

Naturalgas Butadiene

•  Observed30%increasein2,3BDOyieldsontopof30%increaseachievedduringthefirstquarter

•  2,3BDOtestproducFonrunscompletedinpilotplant

•  Providing2,3BDOproducedtochemicalcatalystcompaniesforconversiontobutadieneandqualitytesFng

•  AnFcipatesiteselecFonforsmall-scalefacilitybyyearendandsubsequentlyiniFaFngdesignofplantwithprojectedgroundbreakingin2018

Intrexon’s500LPilotPlant

Intrexon’son-purposebutadieneprocessan(cipatedtohaveCOGSsub$1,000permetricton


HarvestIntrexonEnterpriseFund

→ADSkincare,Inc.Advancedtopicaldeliverysystemtoimproveskinelas(city,firmnessandreduc(onoffinelinesandwrinkles

→CRSBio,Inc.Targeteddeliveryofan(bodiesfortreatmentofchronicrhinosinusi(s

→ExotechBio,Inc.Innova(veexosomeplaòrmfordeliveringtherapeu(cRNAusingselecttargets

→GentenTherapeu;cs,Inc.ActoBio(cs®expressionofglutenpep(destotreatceliacdisease

→RelieveGene;cs,Inc.Non-opioidgenetherapyapproachforneuropathicpainresultantfromcancer

→ThriveAgrobio;cs,Inc.ActoBio(cs®toexpressnutri(veproteinstosupportintes(nalmatura(onandfunc(onandenhancenutrientabsorp(oninearlyweanedpigs


ThriveAgrobioFcs:NutriFonforWeanlingPigs

TheProblem:•  By2050globalconsumpFonof

animalproteinwillbetwo-thirdshigherthancurrentlevels

TheOpportunity:•  Porkisthemostwidelyeatenmeatin

theworldtodayaccounFngfor36%ofglobalmeatconsumpFon

•  WorldwideproducFonofindigenouspigmeatin2010was$168billion

•  HealthyproducFonwillbevitaltomeetgrowingdemandinasustainablemanner

OurSolu;on:UFlizeIntrexon’sActoBioFcs®plagormtodevelopacost-effecFvebiologicthateasilyintegratesintocurrentcommercialporkproducFonsystemsenabling:

•  Increasedgrowthperformance•  Improvedfeedefficacy•  Amoresustainablefoodsupply

Sources:h`p://www.fao.org/news/story/en/item/116937/icode/;h`p://www.fao.org/ag/againfo/themes/en/meat/backgr_sources.html;h`p://www.fao.org/docrep/019/i3440e/i3440e.pdf


LeveragingActoBioFcs®toImproveFeedEfficiency

Goal:TodevelopanadvancedfeedaddiFveforimprovedguthealthandpigletweaningoutcomesApproach:UFlizeActoBioFcs®plagormtoexpressnutriFveproteinstargetedforthegastrointesFnaltract2017Milestones:o  PosiFvedatafromaninvivoanimalstudy;9.6%to12.4%

moretotalweightgainover3weekdosingperiodinpigso  Completeddevelopmentofcommerciallyrelevant

formulaFonwithfavorablecostofgoods

Nextsteps:o  Largepigstudyusingcost-effecFveformulaFonasafeed

addiFve

HealthSectorAndrewLast,Ph.D.–ChiefOperaFngOfficer


ClinicalDevelopmentOutlookfor2017

PaFentpopulaFon#basedonUnitedStatesonly;*EsFmatednewcasesperyear;**ZIOPHARMplanstoiniFatepivotaltrialin2017

Indica;on Gene/CellTherapy Pa;ent# Phase XONCost XONEconomicsRecurrentGlioblastoma Ad-RTS-IL12 >10,000* Phase3** 0 20%OpProfits

RecessiveDystrophicEB FCX-007 2,500 Phase1/2 0 14%NetSales

Adv.LymphoidMalignancies Non-viralSBCD19+CART >80,000* Phase1 0 20%OpProfits

Relapsed/RefractoryAML ViralCD33+CART <8,000* Phase1 0 20%OpProfits

PediatricBrainTumors Ad-RTS-IL12 >3,000 Phase1 0 20%OpProfits

RecurrentGlioblastoma Ad-RTS-IL12&Checkpoint >10,000* Phase1 0 20%OpProfits

Indica;on Gene/CellTherapy Pa;ent# IND XONCost XONEconomicsAML Off-the-ShelfNK ~20,000* 2017 0 20%OpProfits

LinearScleroderma FCX-013 ~40,000 2017 0 14%NetSales

OralMucosiFs ActoBioFcsAG013 ~500,000 2017 0 12%NetSales

Clostridiumdifficile LanFbioFcsOG716 ~500,000* 2017 0 25%OpProfits

SolidTumors SleepingBeautyTCR n/a 2017 n/a n/a

WetAMD AAV-RTS >1million 2017 50%(JV) >50%OpProfits

T1Diabetes ActoBioFcs >1.25million 2017 50%(JV) 50%OpProfits

CardiacDisease pXoXMulF-Gene >20million 2017 75%(Sub) 75%OpProfits

Upto8addi*onalINDsfiledbyyearend2017


UFlizingSleepingBeautySysteminT-CellTherapiesTarge;ngNeoan;gensinSolidTumorsWithTCR-

ModifiedTCellsUsingNon-ViralSleepingBeautySystem CARs:Intrexon,ZIOPHARM,&MerckKGaA•  DisFncFvemethodcentersonproprietaryRTS®

plagormtoregulateexpressionofmembrane-boundinterleukin-15co-expressedwithCARsandSleepingBeautynon-viralgeneintegraFon

•  IL-15iskeydriveroftherapeuFceffectinCAR+Ttherapy*

•  CARtargetsareexpressedonawiderangeofcancers,includinghematologicandsolidtumors

TCRs:Intrexon,ZIOPHARM,&NCI

•  CRADAwithNCIforthedevelopmentofACT-basedimmunotherapiesgeneFcallymodifiedusingtheSleepingBeautysystemtoexpressTCRsforthetreatmentofsolidtumors

•  SleepingBeautyusedtoexpressneoanFgen-specificTCRstodevelopindividualizedimmunotherapiesforpaFentswithcancer

*JournalofClinicalOncology.2017Mar14:JCO2016713024:LymphomaremissionscausedbyCD19-specificCAR+Tcellsareassociatedwithelevatedseruminterleukin-15levels;NatureMedicine22,26–36(2016;MolecularTherapeuFcs.2016Jun;24(6):1078-89


Q2ProgressinOncologyGene&CellTherapies

0 10 20 30 40 50 60 70 80 900

20

40

60

80

100Vehicle/VehicleAd 5e9+V 10 mg/m2

Days

Perc

ent S

urviv

al

0 20 40 60 800

20

40

60

80

100Vehicle/VehicleAd+V 30mg/m2 qdx14antiPD1 15mg/m2 q4dx5Ad+V 30mg/m2 +antiPD1 15mg/m2

Days

Perc

ent S

urvi

val

Pon;neGliomaPre-clinicalStudy

0 10 20 30 40 50 60 70 80 900

20

40

60

80

100Vehicle/VehicleAd 5e9+V 10 mg/m2

Days

Pe

rce

nt

Su

rviv

al

An;-PD-1Combina;onPre-clinicalStudyZIOPHARMPhase1studyforrecurrentglioblastoma(rGBM)•  UpdateatASCOreportedmedianoverall

survivalof12.5months,withmeanfollow-upof9.2months(20mgcohort,N=15)

•  Comparesfavorablytohistoricalcontrols

Enrollmentinstereotac;carmhasbegun•  PaFentsnotscheduledforresecFon•  Runwaytopediatric&anF-PD-1

combinaFonstudies

ZIOPHARMannouncedacceptanceofINDforCD-33specificCARTcelltherapy•  Expectstotreat1stpaFentinQ3’2017

0 20 40 60 800

20

40

60

80

100Vehicle/VehicleAd+V 30mg/m2 qdx14antiPD1 15mg/m2 q4dx5Ad+V 30mg/m2 +antiPD1 15mg/m2

Days

Per

cen

t Su

rviv

al

Vehicle/VehicleAd+V30mg/m2qdx14anFPD115mg/m2q4dx5Ad+V30mg/m2+anFPD115mg/m2

Vehicle/VehicleAd5e9+V10mg/m2


RareDiseases

FCX-007RareSkinDiseaseGeneTherapy(FibrocellScience):•  DataSafetyMonitoringBoardrecommendedconFnuaFonofPhase1/2clinicaltrialfortreatment

ofrecessiveepidermolysisbullosa(RDEB)followingplannedreviewofsafetydatafromfirstadultpaFentdosed

•  CompleteddosingoffirstcohortofthreeadultpaFentsinPhase1porFonoftheclinicaltrial

FCX-013RareSkinDiseaseGeneTherapy(FibrocellScience):•  GrantedRareDiseaseDesignaFonforFCX-013forthetreatmentofmoderatetoseverelinear

scleroderma•  Highlightedpre-clinicaldataforFCX-013atthe20thAnnualMeeFngoftheAmericanSocietyof

Gene&CellTherapy


CompleFonofGenVecAcquisiFon

→DevelopinganextgeneraFonviralplagormwithsignificantlyhigherpayloadcapacity(exceeding30kb)comparedtocurrentviraldeliverymethods(4.5kb–9kb)

→Willfurtheradvancethefieldofgene-basedmedicinebyenablingdeliveryofmulFpletherapeuFceffectorsnotpossiblewithcurrentviraldeliverysystems

→RTS®plagormcombinedwithGenVec’sAdV-basedtechnologyisprojectedtoacceleratecu�ng-edgegenetherapiesthatregulateinvivoexpression

•  VectorswithnoorverylowseroprevalenceinthehumanpopulaFon•  Non-integraFngtransgenelimitsprobabilityofdisturbanceofvitalcellulargenes•  EfficienttransducFonindividingcellsandnon-dividingcells•  Largepackagingcapability(upto12kb)withmulFpleexpressioncasseès•  ImprovedsafetywithmulFpledeleFonsinvectorgenomes•  Administeredtoover3,000clinicalstudysubjects•  Scalableplagormwithefficientmanufacturingprocessanda`racFvecostofgoods

AdenoVerse™Strengths

PrecigenHelenSabzevari,Ph.D.-SVP,HumanTherapeuFcsandHeadofR&DforPrecigen


EvoluFonofPrecigen:NewModelforBioPharma

•  Uniqueposi(onamongPharmaandBiotech

•  Comprehensivesuiteoftechnologyplaòrms,throughinven(onandacquisi(on,underoneroof

•  Crea(onofuniqueinternalporòlioforR&Dinvarious

therapeu(careasbasedoncombina(onsofplaòrmsincludingbiologics,gene(cengineering,immunology,microbiome,vaccines,amongothers

•  Leadingposi(oninsingleandmul(geneprogrammingwith

limitedoff-targeteffects

•  Wellposi(onedtocapitalizeonthesubstan(alpromiseofengineeringbiologytosolvecri(calissuesinhumanhealthandpersonalizedcare

PrecigenTechnologyPlaJorm

Precise&ControlledTherapy


CAR-TTherapy:EarlyPromiseandChallenges

•  Cu�ngedgeofcancerimmunotherapyo  FirstFDAapprovalexpectedin2017for

hematologicalmalignancy

•  CAR-TcellsexpandinpaFentsuponengagementwithanFgenexpressingtumor/normalcells

•  Majorchallengeofcurrentapproachesissignificanttoxicityduetolackofcontrolo  CytokineReleaseSyndrome(CRS)o  TumorLysisSyndromeo  Neurotoxicity

•  LimitaFonsofcurrentapproacheso  ExpressionofanFgenonnormalFssueso  AnFgenlossandheterogeneous

expressionofanFgen

Kenderianetal.,CancerResearch,2014


RegulaFngCAR-TCells:RheoSwitch®andKillSwitch

TransgeneexpressioncanbeturnedONandOFFindosedependentmanner

Intrexon’splagormenablingcontroloverefficacyandsafetyofCAR-Tcells

RTS®controlledco-expressionofcytokines

RTS®controlledexpressionofCAR

KillSwitchforselecFvedepleFonofCAR-Tcells


KillSwitch

GeneSwitchControlofCARExpression

4,500

5,500

6,500

7,500

8,500

9,500

ON OFF ON

CARExpressionRheoSwitch®

VeledimexONVeledimexOFF

CAR

!CAR

!CARCAR


ImprovedPersistencewithRTS®ControlledmbIL-15

VeledimexOFF

0

50,000

100,000

150,000

200,000

250,000

ON OFF ON

mbIL-15Expression

mbIL-15mRNALevels

FoldChangeinmbIL-15mRNAoverCARonlycontrol

CAR

!

"

CAR

mbIL-15

CAR

VeledimexON

0.0

20.0

40.0

60.0

80.0

100.0

3 7 10 14%CellSurvial

Daysinculturefollowingcytokineremoval

CAR-TCellSurvival

•  VeledimexdosedependentexpressionofmbIL-15canbeturnedONandOFF

•  ImprovedpersistenceofCAR-Tcellsbyco-expressionofmbIL-15onlyinpresenceofveledimex

CARmbIL-15

!CAR

mbIL-15

CAR

"mbIL-15


TregsPlayAMajorRoleInAutoimmuneDiseases

InflammatorybowlDisease(IBD) T1diabetes(T1D)

Mul;pleSclerosis(MS)

Lupus(SLE)

RheumatoidArthri;s(RA)

•  RegulatoryTCells(Tregs)arecriFcalforcontrolofimmunesystem•  TregshaveimpairedfuncFonalityinautoimmunediseaseswhere

paFent’simmunesystemisunleashed

Tregs


Intrexon’seTregs:ChangeofParadigm

0

20

40

60

80

100

1:1 1:2 1:4 1:8 1:16 NoTregs

CD4Tcells CD8Tcells

Tcellsupp

ression[%

]

•  OvercominglimitaFonsofnaturallyderivedTregs•  InvitrostudiesdemonstratepotentsuppressionofproliferaFonofeffectorTcellsthroughengineeredTregs(eTregs)

•  PotenFalfornewwaveoftherapeuFcsforvariousautoimmunediseases

Tregs

FinancialOverviewJoelLiffmann–SeniorVicePresident,Finance


SecondQuarterFinancialPerformance

*Non-GAAPfinancialmeasure.

SelectFinancialHighlights 2Q2017 2Q2016

Revenues $54.4M $52.5M

CollaboraFonandLicensingRevenues $28.2M $27.5M

Product&ServicesandOtherRevenues $26.2M $25.0M

AdjustedEBITDA $(2.0)M* $(5.4)*

Impactofchangeindeferredrevenuerelatedtoupfrontandmilestonepayments $(9.4)M $116.1M

BasicEPS $(0.16) $(0.42)

TotalEquity&PreferredStockSecuriFesInConnecFonWithECCs $168.6M $159.0M

Cash,CashEquivalents,andShort-andLong-TermInvestments $157.2M $321.2M


PorgolioExpansion&MaturaFon

June2017

1Over30

January2011

Collabora;ons

June2017

$17.5MM

$392Million

January2011

TAFandReceivedMilestones

June2017

$0 $233Million

January2011

CostRecovery

PorJolioofBackendEconomics

FutureMilestones&Royal;es


Summaryü  Over30collaboraFonsinplacecapitalizingon

ourleadershipposiFonintheengineeringofbiology

ü  StrongcashposiFonwith$157millionincash,cashequivalents,andshort-terminvestments,andequitysecuriFesandpreferredstockvaluedat$168million

ü  Developinghighvaluebio-soluFonswithourcollaboratorsinlargeestablishedmarketswithbuilt-indemand

ü  PosiFonedtodelivermeaningfulreturnstoourshareholdersthroughourscalable,capitalefficientmodelandsuccessfulexecuFonofcurrent&futureopportuniFes

Q&ASession

Documents

Second Quarter 2017 Financial Results and Business Update · representaons and warranFes as may arise under law upon distribuFon of any prospectus or similar oﬀering document by